Abstract: Simulation data associated with a simulation test performed with respect to a first set of training data is obtained. Responsive to a determination that the obtained simulation data satisfies one or more criteria, a second set of training data is obtained, where a size of the second set of training data meets or exceeds a size of the first set of training data. A machine learning model is trained using the second set of training data.

Abstract: A simulation test is run on a first machine learning model trained using first training data historically collected over a time period. The first training data includes a set of training inputs and a set of target outputs. In response to a determination that a result of the simulation test run on the first machine learning model satisfies one or more criteria, a size of the set of target outputs of the first training data is determined. Second training data for training a second machine learning model is obtained. A size of a set of target outputs of the second training data meets or exceeds the size of the target outputs of the first training data. The second machine learning model is trained using the second training data.

Abstract: A simulation test is run on a first machine learning model trained using first training data historically collected over a time period. The first training data includes a set of training inputs and a set of target outputs. In response to a determination that a result of the simulation test run on the first machine learning model satisfies one or more criteria, a size of the set of target outputs of the first training data is determined. Second training data for training a second machine learning model is obtained. A size of a set of target outputs of the second training data meets or exceeds the size of the target outputs of the first training data. The second machine learning model is trained using the second training data.

Abstract: A system and method are disclosed for running a plurality of simulation tests on a first machine learning model to obtain a plurality of results that are each produced during a respective simulation test, the first machine learning model gradually trained using first training data historically collected over a period of time, the first training data comprising a plurality of first training data sets each including a subset of first training inputs and first target outputs associated with one of a plurality of points in time during the period of time, determining a simulation test of the plurality of simulation tests at which corresponding results of the first machine learning model satisfy a threshold condition, wherein the threshold condition is based on historical data at a first point in time of the plurality of points in time, identifying a first training data set of the plurality of first training data sets on which the first machine learning model used during the determined simulation test was trained,

Abstract: A system and method are disclosed for running a plurality of simulation tests on a first machine learning model to obtain a plurality of results that are each produced during a respective simulation test, the first machine learning model gradually trained using first training data historically collected over a period of time, the first training data comprising a plurality of first training data sets each including a subset of first training inputs and first target outputs associated with one of a plurality of points in time during the period of time, determining a simulation test of the plurality of simulation tests at which corresponding results of the first machine learning model satisfy a threshold condition, wherein the threshold condition is based on historical data at a first point in time of the plurality of points in time, identifying a first training data set of the plurality of first training data sets on which the first machine learning model used during the determined simulation test was trained,

Abstract: The present invention relates to an improved process for the preparation of bosentan. In particular it relates to a process for preparing bosentan substantially free from the dimer impurity of formula (II) and the 6-hydroxy impurity of formula (III). The invention also relates to a pharmaceutical composition comprising bosentan and its use in the treatment of endothelin-receptor mediated disorders.

Abstract: A novel process for the preparation of Etravirine comprises the condensing of ethyl cyanoacetate with N-cyanophenylguanidine to obtain an —OH compound of formula (II), which is further converted to a leaving group of formula (III). The compound of formula (III) is optionally protected and brominated to yield compound of formula (IV). The condensation of formula (IV) with 3,5-dimethyl-4-hydroxybenzonitrile yields a compound of formula (VI), and an optional deprotection of the compound of formula (VI) results in Etravirine.

Abstract: The present invention relates to novel crystalline forms of bosentan and processes for their preparation. Further, the invention relates to pharmaceutical compositions comprising said crystalline forms and use of said compositions in the treatment of patients suffering from endothelin receptor mediated disorders, for example, cardiovascular disorders such as hypertension, pulmonary hypertension, ischemia, vasospasm and angina pectoris.

Abstract: A novel process for the preparation of Etravirine comprises the condensing of ethyl cyanoacetate with N-cyanophenylguanidine to obtain an —OH compound of formula (II), which is further converted to a leaving group of formula (III). The compound of formula (III) is optionally protected and brominated to yield compound of formula (IV). The condensation of formula (IV) with 3,5-dimethyl-4-hydroxybenzonitrile yields a compound of formula (VI), and an optional deprotection of the compound of formula (VI) results in Etravirine.

Abstract: Novel polymorphic forms of bosentan and processes for their preparation are disclosed. Further, pharmaceutical compositions comprising said polymorphic forms and the use of said compositions in the treatment of patients suffering from endothelin receptor mediated disorders, for example, cardiovascular disorders such as hypertension, pulmonary hypertension, ischemia, vasospasm and angina pectoris are disclosed.

Abstract: The present invention relates to a novel crystalline form of sunitinib free base designated form I and to processes for its preparation. The invention also relates to its use as an API and in the preparation of various forms of sunitinib. Further, the invention relates to pharmaceutical compositions comprising the novel crystalline form and salts, solvates and hydrates prepared according to the invention, and to the uses of said pharmaceutical compositions in the treatment and/or prevention of cancer.

Abstract: The present invention relates to novel intermediates and further to the use of said intermediates in processes for the preparation of indolinone derivatives, in particular 3-pyrrole substituted 2-indolinones having amide moieties on the pyrrole ring. Such compounds are useful in die treatment of abnormal cell growth, such as cancer, in mammals.

Abstract: The present invention relates to novel polymorphs of sunitinib free base designated form II and form III and to processes for their preparation. The invention also relates to their use as APIs and in the preparation of various forms of sunitinib. Further, the invention relates to pharmaceutical compositions comprising said novel polymorphs and salts, solvates and hydrates prepared according to the invention, and to the uses of said pharmaceutical compositions in the treatment and/or prevention of cancer.

Abstract: The present invention, relates to novel processes for the preparation of sunitinib malate formula (I), pharmaceutical compositions comprising said polymorph and the use of the said pharmaceutical compositions in the treatment of various forms of cancer.

Abstract: The present invention relates to novel polymorph forms III and IV of sunitinib malate, pharmaceutical compositions comprising the novel polymorphs and the use of the pharmaceutical compositions. The present invention further relates to processes for the preparation of polymorph form I, III and IV of sunitinib malate.

Abstract: Novel polymorphic forms of bosentan and processes for their preparation are disclosed. Further, pharmaceutical compositions comprising said polymorphic forms and the use of said compositions in the treatment of patients suffering from endothelin receptor mediated disorders, for example, cardiovascular disorders such as hypertension, pulmonary hypertension, ischemia, vasospasm and angina pectoris are disclosed.

Abstract: The present invention relates to an improved process for the preparation of bosentan. In particular it relates to a process for preparing bosentan substantially free from the dimer impurity of formula (II) and the 6-hydroxy impurity of formula (III). The invention also relates to a pharmaceutical composition comprising bosentan and its use in the treatment of endothelin-receptor mediated disorders.